Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study
An erratum to this article was published (J Clin Endocrinol Metab, 18 Jan 2024 ↗)
Authors' conclusion
The increased F:B ratio observed in GD/GO mirrors our finding in a murine model comparing TSHR-immunized with control mice. We defined a microbiome signature and identified changes associated with autoimmunity as distinct from those due to hyperthyroidism. Persistence of TRAb is predictive of relapse; identification of these patients at diagnosis, via their microbiome, could improve management with potential to eradicate Clostridiales.
Study context
- Population
- Patients with Graves disease (GD) (hyperthyroid, TRAb positive at recruitment), with Graves orbitopathy (GO) of varying severity, and healthy controls, 4 European countries
- Participants
- 105 vs 41
- Exposure
- GD/GO patients vs healthy controls
- GD/GOn = 105
- Healthy controls (HCs)n = 41reference
- Outcome
- Fecal microbiota composition
Methodological detailsmulticenter, 4 European countries
- Multicenter
- 4 European countries
Main finding
As reported in the abstract
Differential abundance of genera in patients, most skewed in mild GO
15 genera
Observational data: associations, not effects.
Further findings
Persistence of TRAb >200 days after starting antithyroid drug treatment · longitudinal
- Presence of Clostridiales at diagnosis correlated with persistence of TRAb
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →